References
- World Health Organization Collaborative Study on cardiovascular disease and steroid hormone contraception. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. Lancet 1995; 346: 1575–82
- World Health Organization Collaborative Study on cardiovascular disease and steroid hormone contraception. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 1995; 346: 1582–8
- Bloemenkamp K WM, Rosendaal F R, Helmerhorst F M., Billler H R., Vandenbroucke J R. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 1995; 346: 1593–6
- Jick H, Jick S S, Gurewich V., Myers M W, Vasilakis C. Risk of ideopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995; 346: 1589–93
- Spitzer W O, Lewis M A., Heinemann L AJ, Thorogood M., MacRae K D. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. BMJ 1996; 312: 83–7
- Lewis M A., Spitzer W O, Heinemann L AJ, MacRae K D, Bruppacher R, Thorogood M. Third generations oral contraceptives and risk of myocardial infarction: an international case-control study. BMJ 1996; 312: 88–90
- Lewis M A, Heinemann L AJ, MacRae K. D., Bruppacher R., Spitzer W O. The increased risk of venous thromboembolism and the use of third generation progestagens: role of bias in observational research. Contraception 1996; 54: 5–13
- Lidegaard Ø. Oral contraception in Denmark in 1983. (Da). Ugeskr Laeger 1984; 146: 1172–4
- Lidegaard Ø. Use of oral contraceptives in Denmark from 1980–1990 and smoking habits among fertile women in 1990. (da). Ugeskr Laeger 1993; 155: 3550–8
- Thorogood M, Vessey M P. Trends in use of oral contraceptives in Britain. Br J Fam Plann 1990; 16: 41–56
- Lidegaard Ø, Overgaard K, Hauch O. The oral contraceptive user. Acta Obstet Gynecol Scand 1988; 67: 27–31
- Thorogood M, Vessey M. Oral contraceptive prescribing in the presence of risk factors. Br J Fam Plann 1991; 17: 2–3
- Sartwell P E, Masi A T, Arthes F G, Greene G R, Smith H E. Thromboembolism and oral contraceptives: An epidemiologic case-control study. Am J Epidemiol 1969; 90: 365–80
- Böttiger L E, Boman G, Eklund G, Westerholm B. Oral contraceptives and thromboembolic disease: Effects of lowering oestrogen content. Lancet 1980; i: 1097–1101
- Böttiger L E, Westerholm B. Oral contraceptives and thromboembolic disease. Acta Med Scand 1991; 190: 455–63
- Vessey M P, Doll R. Investigation of relation between use of oral contraceptives and thromboembolic disease. A further report. Br Med J 1969; 2: 651–7
- Lidegaard Ø. Oral contraception and risk of a cerebral thromboembolic attack: results of a case-control studv. BMJ 1993; 306: 956–63